ATE213507T1 - Methode zur bindung von material an das beta- amyloid-peptid - Google Patents
Methode zur bindung von material an das beta- amyloid-peptidInfo
- Publication number
- ATE213507T1 ATE213507T1 AT94931974T AT94931974T ATE213507T1 AT E213507 T1 ATE213507 T1 AT E213507T1 AT 94931974 T AT94931974 T AT 94931974T AT 94931974 T AT94931974 T AT 94931974T AT E213507 T1 ATE213507 T1 AT E213507T1
- Authority
- AT
- Austria
- Prior art keywords
- beta
- amyloid peptide
- binding material
- immunoglobulin
- preserving
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/804—Radioisotope, e.g. radioimmunoassay
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/839—Nerves; brain
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13947093A | 1993-10-20 | 1993-10-20 | |
| PCT/US1994/012101 WO1995011311A1 (en) | 1993-10-20 | 1994-10-20 | METHOD OF BINDING MATERIAL TO THE β-AMYLOID PEPTIDE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE213507T1 true ATE213507T1 (de) | 2002-03-15 |
Family
ID=22486818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94931974T ATE213507T1 (de) | 1993-10-20 | 1994-10-20 | Methode zur bindung von material an das beta- amyloid-peptid |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6294340B1 (de) |
| EP (1) | EP0728215B1 (de) |
| JP (1) | JPH09506170A (de) |
| AT (1) | ATE213507T1 (de) |
| AU (1) | AU683703B2 (de) |
| CA (1) | CA2174501A1 (de) |
| DE (1) | DE69429925T2 (de) |
| ES (1) | ES2173130T3 (de) |
| WO (1) | WO1995011311A1 (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| US6923964B1 (en) | 1997-12-02 | 2005-08-02 | Neuralab Limited | Active immunization of AScr for prion disorders |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| US6294171B2 (en) * | 1999-09-14 | 2001-09-25 | Milkhaus Laboratory, Inc. | Methods for treating disease states comprising administration of low levels of antibodies |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| US20030082191A1 (en) | 2001-08-29 | 2003-05-01 | Poduslo Joseph F. | Treatment for central nervous system disorders |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| EP1633786A4 (de) * | 2002-10-09 | 2007-07-25 | Rinat Neuroscience Corp | Verfahren zur behandlung der alzheimer-krankheit mit antikörpern gegen amyloid-beta-peptid und zusammensetzungen daraus |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
| GEP20115195B (en) * | 2004-07-30 | 2011-04-11 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and use thereof |
| ES2396555T3 (es) | 2004-12-15 | 2013-02-22 | Janssen Alzheimer Immunotherapy | Anticuerpos que reconocen péptido beta amiloide |
| PE20061329A1 (es) | 2004-12-15 | 2006-12-08 | Neuralab Ltd | Anticuerpos ab humanizados para mejorar la cognicion |
| PE20061323A1 (es) | 2005-04-29 | 2007-02-09 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos |
| BRPI0619249A2 (pt) | 2005-11-30 | 2011-09-20 | Abbott Lab | anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos |
| PT1976877E (pt) | 2005-11-30 | 2014-04-29 | Abbvie Inc | Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| EP2124952A2 (de) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Verfahren zur behandlung von amyloidosen |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| SI2182983T1 (sl) | 2007-07-27 | 2014-09-30 | Janssen Alzheimer Immunotherapy | Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| WO2011002494A1 (en) * | 2009-07-01 | 2011-01-06 | University Of Tenessee Research Foundation | Use of immunoglobulin heavy and light chains or fragments therof to bind to aggregated amyloidogenic proteins |
| EP2558494B1 (de) | 2010-04-15 | 2018-05-23 | AbbVie Inc. | Amyloid-beta-bindende proteine |
| CN105348387B (zh) | 2010-08-14 | 2020-08-25 | Abbvie 公司 | β淀粉样蛋白结合蛋白 |
| EP3658172A4 (de) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | Behandlung von krebs durch blockierung der interaktion von tim-3 und seinem liganden |
| CN113711036B (zh) | 2019-01-30 | 2025-03-18 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4271140A (en) * | 1978-01-23 | 1981-06-02 | Baxter Travenol Laboratories, Inc. | Method and composition for double receptor, specific binding assays |
| US4891313A (en) * | 1988-01-21 | 1990-01-02 | Boehringer Manheim Corporation | Method for determination of a component of a sample |
| JP2980677B2 (ja) | 1990-04-27 | 1999-11-22 | マクマイケル,ジョン | 不正常なアミロイドβタンパク質と関連する中枢神経系疾患状態の治療のための方法および組成物 |
| WO1992003474A1 (en) | 1990-08-24 | 1992-03-05 | President And Fellows Of Harvard College | METHOD OF INTERFERING WITH FORMATION OF α-ANTICHYMOTRYPSIN-β-PROTEIN COMPLEX AND SYNTHETIC PEPTIDES FOR USE THEREIN |
| US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
-
1994
- 1994-10-20 DE DE69429925T patent/DE69429925T2/de not_active Expired - Fee Related
- 1994-10-20 AU AU80867/94A patent/AU683703B2/en not_active Ceased
- 1994-10-20 JP JP7512235A patent/JPH09506170A/ja active Pending
- 1994-10-20 WO PCT/US1994/012101 patent/WO1995011311A1/en not_active Ceased
- 1994-10-20 AT AT94931974T patent/ATE213507T1/de not_active IP Right Cessation
- 1994-10-20 EP EP94931974A patent/EP0728215B1/de not_active Expired - Lifetime
- 1994-10-20 CA CA002174501A patent/CA2174501A1/en not_active Abandoned
- 1994-10-20 ES ES94931974T patent/ES2173130T3/es not_active Expired - Lifetime
-
1996
- 1996-10-21 US US08/734,490 patent/US6294340B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6294340B1 (en) | 2001-09-25 |
| EP0728215A4 (de) | 1998-09-16 |
| CA2174501A1 (en) | 1995-04-27 |
| AU8086794A (en) | 1995-05-08 |
| EP0728215A1 (de) | 1996-08-28 |
| JPH09506170A (ja) | 1997-06-17 |
| AU683703B2 (en) | 1997-11-20 |
| DE69429925D1 (de) | 2002-03-28 |
| WO1995011311A1 (en) | 1995-04-27 |
| EP0728215B1 (de) | 2002-02-20 |
| ES2173130T3 (es) | 2002-10-16 |
| DE69429925T2 (de) | 2002-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69429925D1 (de) | METHODE ZUR BINDUNG VON MATERIAL AN DAS Beta-AMYLOID-PEPTID | |
| DK0724456T3 (da) | CD40-Antistoffer | |
| ATE412432T1 (de) | Internalisierende erbb2 antikörper | |
| DE69233735D1 (de) | Bindungsdomänen des Delta-proteins | |
| DE69531679D1 (de) | Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper | |
| ATE177754T1 (de) | Fragmente von prion proteinen. | |
| SE9201331D0 (sv) | Protein l och hybridproteiner daerav | |
| DK1027439T3 (da) | Multivalente antigenbindende proteiner | |
| IL210392A0 (en) | Antibodies that bind to tgf-?? binding proteins with an affinity of 106m-1 and uses thereof | |
| WO2022032003A3 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| DK0812206T3 (da) | Fremgangsmåde til stimulering af en immunrespons | |
| WO1995024481A3 (en) | Humanized monoclonal antibodies against human interleukin-4 | |
| DK0802924T3 (da) | Lægemiddel til forlænget immunsuppression og eliminering af tumorceller | |
| DE59508137D1 (de) | Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine | |
| ATE335504T1 (de) | Humanisierte antikörper zur erkennung von verotoxin ii sowie zellinie zur herstellung derselben | |
| GB2333295A (en) | Modified protein G and fragments thereof | |
| HUP0003029A2 (hu) | Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |